Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Stomach Neoplasms 1Solitary Fibrous Tumor, Pleural 1Recurrence 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 28Pemetrexed 22Gemcitabine 10Nivolumab 9Carboplatin 9pembrolizumab 8tremelimumab 5durvalumab 5atezolizumab 5Radiotherapy 5Doxorubicin 4Chemotherapy, Adjuvant 4Vinorelbine 3Ipilimumab 3Bortezomib 3Bevacizumab 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2sodium thiosulfate 2sargramostim 2niraparib 2nintedanib 2liposomal doxorubicin 2lenvatinib 2defactinib 2cemiplimab 2cediranib 2amatuximab 2Trabectedin 2Neoadjuvant Therapy 2Mitomycin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma, Malignant × rilotumumab × Clear all
NCT01105390 2013-08-02

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

Data powered by HemOnc (CC BY 4.0) Colophon âš¡